MAIL MAN

[righty]

VIVK is a stock on the move, make sure you're watching it
Mon, December 14, 2009 7:35:35 AMFrom: BeaconEquity.com <[e-mail]> Add to Contacts



--------------------------------------------------------------------------------




VIVK is a stock on the move, make sure you're watching it

The development of substantive technologies and cures for complex human conditions, illnesses and diseases require a sophisticated approach with contribution from many areas of scientific expertise.

Our latest stock idea—Vivakor, Inc. (VIVK) is a biotechnology company with transdisciplinary research that develops and acquires products that extend or improve life.

It divides its research efforts into FOUR primary areas of medical and biotechnological development. These divisions are…

Molecular Medicine
Electro-Optics
Biological Handling
Natural and Formulary Products
Vivakor generates revenues in a number of ways:


Product Licensing and joint ventures with manufacturers, marketing/distribution partners
Outright sale of the technology

Technology spin-off in a subsidiary where the product will be manufactured, marketed and sold directly to customers and clients.
In fact, offering what we feel could have tremendous growth potential, VIVK has several promising technologies including ….

Vivathermic Vials---VIVK estimates that it may capture up to 1.5% of the $1.9 billion market for laboratory bioconsumables by 2011 and industry leading distributors anticipate a 3% annual growth in cryovial sales segment.

VIVK has developed specialized cryovials that accommodate an improved method of cryopreservation of cells, blood, and other bio-materials. The company recently announced distribution of its VivaThermic products to the rapidly growing biotech/biopharma industries in India through its agreement with Pro Lab Marketing Pvt. Ltd

So why does management feel that their Vivathermic vial is superior to the competition?

Well, VivaThermic Vials claim to thaw the sample 3 times faster than market leading vials.

It also has a unique 2-in-1 design. This dual functionality is expected to improve customer production efficiency and reduce time and material costs by eliminating the need to transfer samples between vials and microcentrifuges.

Vivaslices-- This technology is a software upgrade to older MRI units that allow the unit to achieve HIGHER RESOLUTION using a patented algorithm. The underlying algorithm may be useful in the determination of blood flow velocity measures in imaged tissues.

Such information would be valuable in accessing areas of blood flow constriction from plaques or other hematologic deposits.

Management believes this may help physicians better diagnose, predict and assess stroke and related diseases involving blood flow obstruction in this $300M market.

VivaSight--VIVK has developed a device that may modernize screening of pre-verbal and pre-literate children for ocular disorders. Already a $50 million a year market, this type of screening is increasingly required by state governments prior to enrollment in the public school system.

The company believes this technology (device, software and accessories) could modernize child vision screening. With anticipation of legislatively mandated pediatric vision screening, demand for these products could skyrocket. The Company is anticipating launching its product next summer!

VivaBlend--VIVK's PROPRIETARY balanced blend of more than 18 different sources of phytochemical extracts from antioxidant rich bioactive fruits and vegetables tested by the USDA that can be added to many consumer foods, drinks and nutraceuticals as a convenient daily source of important antioxidants and other critical bioactive phytochemicals.

And speaking of Nutraceuticals…

Last Thursday VIVK announced it has received a $5 million licensing and purchase agreement for its Nutraceutical products.

The agreement exclusively licenses to Regeneca International distribution rights to a new cutting-edge nutraceutical formulation developed by VIVK and provides for the development of future formulations by the Company for Regeneca.

Regeneca has committed to purchase from Vivakor a minimum of $5 million in product over the next three years and Vivakor will receive a 15% ownership interest in Regeneca's outstanding common stock and will be the EXCLUSIVE SUPPLIER of the licensed product to Regeneca. To read the full story Click Here.

So what does VIVK’s price chart suggest? Well, consider this…

After having recently given way to profit-taking on contracting downside volume, upside volume spikes are returning to the stock suggesting heavy accumulation at current levels.
The stock is currently at (or very near) the level it was at before its last major move higher. Could it be poised to retest its recent high?
The MACD’s downside momentum may be losing steam suggesting a rally may be on the way.
The stochastics is DEEPLY OVERSOLD indicating that the stock may have fallen too far and too fast…and that buying interest may return very soon.




So do your OWN homework on VIVK and add it to your watch-list right away.
With its rapidly growing intellectual property assets, products already in clinical validation trials, and products in development (clinical bio-medical sensor, anemia and wound monitor and a burn and melanoma MSI), we think VIVK could offer an excellent trade opportunity for our members, both long-term and short-term.

We are excited to bring this one to our members.







To view the disclaimer visit http://www.beaconequity.com/emails07/vivk/VIVK.html

Beacon Equity Research | 4828 S. Broadway #182 | Tyler, TX 75703





--------------------------------------------------------------------------------
If you no longer wish to receive these emails, please reply to this message with "Unsubscribe" in the subject line or simply click on the following link: Unsubscribe

--------------------------------------------------------------------------------
BeaconEquity.com
4828 S. Broadway #182
Tyler, Texas 75703
US
Read the VerticalResponse marketing policy.